Literature DB >> 11786196

Isolation and characterization of serum procalcitonin from patients with sepsis.

W Weglöhner1, J Struck, C Fischer-Schulz, N G Morgenthaler, A Otto, C Bohuon, A Bergmann.   

Abstract

Procalcitonin (PCT) is one of the precursors in the synthesis of calcitonin in thyroidal C-cells and other neuroendocrine cells. PCT and other calcitonin precursors are elevated in the serum of many conditions leading to systemic inflammatory response syndrome. The measurement of PCT in patients suffering from severe bacterial infections is a useful tool for the diagnosis of sepsis. Furthermore, therapeutic decisions are often based on the increase or decline of serum PCT levels. PCT was reported to have 116 amino acids. The aim of our study was the determination of the primary structure of serum PCT from septic patients. Sera containing high PCT-concentrations (>100 ng/ml) were collected from 22 patients with severe sepsis and were pooled for further purification (12.7 microg total concentration of PCT). Pooled PCT was purified on a CT 21-immunoaffinity column, further purified by reversed phase HPLC, and the resulting pure PCT was digested with endoproteinase Asp-N. N-terminal Edman sequencing showed that the first two amino acids (Ala-Pro) of the proposed pro-peptide were missing. Further analyses by MALDI-TOF mass spectroscopy resulted in a distinct mass signal of 12640 Da +/- 0.1%, which is in concordance with the theoretical molecular weight of the N-terminal truncated form (12628 Da). As opposed to previous suggestions, we could not detect any chemical modifications of PCT. In summary, we could demonstrate that PCT in the serum of septic patients is a peptide of only 114 amino acids, instead of the predicted 116 amino acids, lacking the N-terminal dipeptide Ala-Pro. This information on the primary structure of PCT might help in further studies on the physiological role of PCT during sepsis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11786196     DOI: 10.1016/s0196-9781(01)00541-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  7 in total

Review 1.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

2.  Procalcitonin and pneumonia: is it a useful marker?

Authors:  Mirjam Christ-Crain; Beat Müller
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

Review 3.  Regulation and Dysregulation of Endothelial Permeability during Systemic Inflammation.

Authors:  Katharina E M Hellenthal; Laura Brabenec; Nana-Maria Wagner
Journal:  Cells       Date:  2022-06-15       Impact factor: 7.666

Review 4.  Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia.

Authors:  Mirjam Christ-Crain; Steven M Opal
Journal:  Crit Care       Date:  2010-02-08       Impact factor: 9.097

5.  DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients.

Authors:  Sawako Kato; Bengt Lindholm; Peter Stenvinkel; Tomas J Ekström; Karin Luttropp; Yukio Yuzawa; Yoshinari Yasuda; Yoshinari Tsuruta; Shoichi Maruyama
Journal:  Nephron Extra       Date:  2012-06-20

6.  Markedly elevated procalcitonin in early postoperative period in pediatric open heart surgery: a prospective cohort study.

Authors:  Etsuko Minami; Shoji Ito; Takeshi Sugiura; Yoshihito Fujita; Hiroshi Sasano; Kazuya Sobue
Journal:  J Intensive Care       Date:  2014-06-20

7.  Bio-Functionalized Magnetic Nanoparticles for the Immunoassay of C-Reactive Protein and Procalcitonin in Cervicovaginal Secretions of Pregnant Women with Preterm Prelabor Rupture of Membranes to Predict Early-Onset Neonatal Sepsis.

Authors:  Sau Xiong Ang; Chie-Pein Chen; Fang-Ju Sun; Chen-Yu Chen
Journal:  Int J Nanomedicine       Date:  2022-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.